Le Lézard
Classified in: Transportation, Covid-19 virus
Subject: OFR

Genuine Parts Company Prices $500 Million Of Senior Notes


ATLANTA, Oct. 28, 2020 /PRNewswire/ -- Genuine Parts Company (NYSE: GPC) announced today the pricing of its $500 million 1.875% senior notes due 2030 issued at a price equal to 99.069% of the face value of the notes. The offering is expected to settle on Thursday, October 29, 2020. GPC intends to use the net proceeds from this offering to repay outstanding indebtedness, in part to satisfy certain debt repayment obligations.

GPC has filed a registration statement, including a prospectus and preliminary prospectus supplement, with the SEC for this offering. Prospective investors should read the prospectus in that registration statement, the preliminary prospectus supplement and other documents GPC has filed with the SEC for more complete information about GPC and this offering. The documents are available for free by visiting EDGAR on the SEC website at sec.gov.

Alternatively, copies of the preliminary prospectus supplement and the accompanying prospectus may be obtained by contacting the joint book-running managers by calling J.P. Morgan Securities LLC toll free at (866)-803-9204 or writing to J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer or sale of these securities will be made only by means of a prospectus, including a prospectus supplement, forming a part of the related registration statement.

Forward Looking Statements

This press release contains forward-looking statements that represent our current judgment about possible future events.  The Company cautions that its forward-looking statements involve risks and uncertainties, and while we believe that our expectations for the future are reasonable in view of currently available information, you are cautioned not to place undue reliance on our forward-looking statements. Actual results or events may differ materially from those indicated as a result of various important factors. A list and description of these factors (all of which risks may be amplified by the COVID-19 outbreak) can be found in our Annual Report on Form 10-K and our subsequent filings with the U.S. Securities and Exchange Commission. We caution readers not to place undue reliance on forward-looking statements. Forward-looking statements are only as of the date they are made, and the Company undertakes no duty to update its forward-looking statements except as required by law.

SOURCE Genuine Parts Company


These press releases may also interest you

at 03:05
Vagaro, the leading international salon and spa software, and Jack Mead, award-winning hair stylist, salon owner, and educator, officially announced the release of their highly-anticipated Master Class series, delivering expert insights on using the...

at 02:30
Allied Market Research published a report, titled, "Pension Administration Software Market by Component (Solution and Services), Deployment Mode (On-Premise and Cloud), Type (Public Pension and Private Pension), End User (Employers, Pension Plan...

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood...

at 01:05
Teck Resources Limited (Teck) today announced its unaudited first quarter results for 2024. "All outstanding major construction at our QB operation was completed in the first quarter, including the shiploader and molybdenum plant, and we marked the...

24 avr 2024
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...



News published on and distributed by: